BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Cervical cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
13 results:

  • 1. Human Papillomavirus Modulates Matrix Metalloproteinases During Carcinogenesis: Clinical Significance and Role of Viral Oncoproteins.
    Mendonça F; Teles AM; Nascimento MDDSB; Santos APAD; Lopes FF; Paiva A; Brito HO; DA Costa RG
    In Vivo; 2022; 36(6):2531-2541. PubMed ID: 36309355
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, timp-1, timp-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
    Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
    BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. IL-17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38/NF-κB signal pathway.
    Feng M; Wang Y; Chen K; Bian Z; Jinfang Wu ; Gao Q
    PLoS One; 2014; 9(9):e108502. PubMed ID: 25250801
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Significant relation of tissue inhibitor of matrix metalloproteinase-2 and its combination with matrix metalloproteinase-2 to survival of patients with cancer of uterine cervix.
    Wang PH; Ko JL; Yang SF; Tsai HT; Tee YT; Han CP; Lin LY; Chen SC; Shih YT
    Reprod Sci; 2011 Aug; 18(8):798-808. PubMed ID: 21422052
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas.
    Cao XL; Xu RJ; Zheng YY; Liu J; Teng YS; Li Y; Zhu J
    Asian Pac J Cancer Prev; 2011; 12(12):3245-9. PubMed ID: 22471461
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Promoter methylation of p16, DAPK, CDH1, and timp-3 genes in cervical cancer: correlation with clinicopathologic characteristics.
    Jeong DH; Youm MY; Kim YN; Lee KB; Sung MS; Yoon HK; Kim KT
    Int J Gynecol Cancer; 2006; 16(3):1234-40. PubMed ID: 16803511
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (timp-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN.
    Branca M; Ciotti M; Giorgi C; Santini D; Di Bonito L; Costa S; Benedetto A; Bonifacio D; Di Bonito P; Paba P; Accardi L; Syrjänen S; Favalli C; Syrjänen K;
    Anticancer Res; 2006; 26(2B):1543-56. PubMed ID: 16619570
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma.
    Sier CF; Zuidwijk K; Zijlmans HJ; Hanemaaijer R; Mulder-Stapel AA; Prins FA; Dreef EJ; Kenter GG; Fleuren GJ; Gorter A
    Int J Cancer; 2006 Jun; 118(12):2991-8. PubMed ID: 16425263
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (timp 2) in stage IB cervical cancer.
    Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
    Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MMP-2 and timp-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.
    Davidson B; Goldberg I; Kopolovic J; Lerner-Geva L; Gotlieb WH; Ben-Baruch G; Reich R
    Gynecol Oncol; 1999 Jun; 73(3):372-82. PubMed ID: 10366463
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The foundations of successful RT in situ PCR.
    Nuovo GJ
    Front Biosci; 1996 Nov; 1():c4-15. PubMed ID: 9159200
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma.
    Nuovo GJ; MacConnell PB; Simsir A; Valea F; French DL
    Cancer Res; 1995 Jan; 55(2):267-75. PubMed ID: 7812956
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Autologous blood transfusion using recombinant human erythropoietin in radical hysterectomy.
    Yamawaki T; Tanaka H; Takeuchi S; Yanase H; Taniguchi H; Toyoda N
    Asia Oceania J Obstet Gynaecol; 1994 Jun; 20(2):147-53. PubMed ID: 8092959
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.